OncoMatch/Clinical Trials/NCT06132711
Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma
Is NCT06132711 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies non-drug interventions for multiple myeloma.
This is a Single-center, open, single-arm clinical study, the goal of which was to evaluate the safety and efficacy of APRIL-BAFF-Bicephali CAR-T in relapsed and refractory multiple myeloma.The study consisted of four processes: patient enrollment screening; pre-CAR T cell therapy (including leukocyte apheresis, CAR T cell preparation and chemotherapy); inpatient monitoring phase for CAR T cell transfusion; and long-term follow-up phase
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Demographics
Lab requirements
Liver function
ALT and AST <3 times normal; bilirubin <2.0mg / dl
Cardiac function
The patient has no serious heart, liver, kidney and other diseases
ALT and AST <3 times normal; bilirubin <2.0mg / dl; The patient has no serious heart, liver, kidney and other diseases
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06132711 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages